Telix Pharmaceuticals
(NASDAQ) TLX
Telix Pharmaceuticals Financials at a Glance
Market Cap
$3.09B
Revenue (TTM)
$2.00B
Net Income (TTM)
$39.18M
EPS (TTM)
$-0.02
P/E Ratio
-432.70
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Price
$9.12
Volume
3,896
Open
$9.07
Price
$9.12
Volume
3,896
Open
$9.07
Previous Close
$9.12
Daily Range
$8.99 - $9.23
52-Week Range
$6.28 - $20.00
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Price
$9.12
Volume
3,896
Open
$9.07
Previous Close
$9.12
Daily Range
$8.99 - $9.23
52-Week Range
$6.28 - $20.00
TLX News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Telix Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
234
CEO
Christian P. Behrenbruch, PhD, EMBA
Website
www.telixpharma.comHeadquarters
North Melbourne, VIC 3051, AU
TLX Financials
Key Financial Metrics (TTM)
Gross Margin
51%
Operating Margin
2%
Net Income Margin
-1%
Return on Equity
-2%
Return on Capital
2%
Return on Assets
-1%
Earnings Yield
-0.23%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$3.09B
Shares Outstanding
338.89M
Volume
3.90K
Short Interest
0.00%
Avg. Volume
246.93K
Financials (TTM)
Gross Profit
$640.23M
Operating Income
$26.64M
EBITDA
$79.83M
Operating Cash Flow
$25.93M
Capital Expenditure
$56.86M
Free Cash Flow
$82.80M
Cash & ST Invst.
$212.53M
Total Debt
$784.47M
Telix Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$620.44M
+120.2%
Gross Profit
$327.42M
+46.2%
Gross Margin
52.77%
N/A
Market Cap
$3.09B
N/A
Market Cap/Employee
N/A
N/A
Employees
N/A
N/A
Net Income
$7.25M
-137.1%
EBITDA
$28.92M
+25.8%
Quarterly Fundamentals
Net Cash
$571.94M
-640.6%
Accounts Receivable
$207.29M
+220.0%
Inventory
$55.55M
+220.9%
Long Term Debt
$756.51M
+4662.1%
Short Term Debt
$27.95M
+1692.9%
Return on Assets
-0.61%
N/A
Return on Invested Capital
1.81%
N/A
Free Cash Flow
$92.60M
-2441.3%
Operating Cash Flow
$52.55M
-594.6%